Rituximab as first choice for patients with refractory rheumatoid arthritis: cost-effectiveness analysis in Iran based on a systematic review and meta-analysis
Crossref DOI link: https://doi.org/10.1007/s00296-016-3484-5
Published Online: 2016-04-30
Published Print: 2016-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ahmadiani, Saeed
Nikfar, Shekoufeh
Karimi, Somayeh
Jamshidi, Ahmad Reza
Akbari-Sari, Ali
Kebriaeezadeh, Abbas
Text and Data Mining valid from 2016-04-30